Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 13, 2023, detailing key corporate governance actions and shareholder vote outcomes from its Annual Meeting held on June 9, 2023. The most significant governance change involves an amendment to the company's By-Laws to implement its previously disclosed Board leadership succession plan, allowing for the election of two Co-Chairs of the Board. Shareholders overwhelmingly approved routine matters, including the election of Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023, and the advisory vote on executive compensation. The company will continue with annual advisory votes on executive compensation. A shareholder proposal related to access to medicine in intellectual property protection was not approved.
Key Highlights
- 1Amendment to By-Laws to facilitate a Board leadership succession plan, enabling the appointment of two Co-Chairs.
- 2All nominated Class II directors were elected with substantial support.
- 3Shareholders ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023.
- 4An advisory vote to approve executive compensation was passed by a significant majority.
- 5Shareholders determined that future advisory votes on executive compensation will occur annually.
- 6A shareholder proposal regarding access to medicine in intellectual property matters was defeated.